Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
NCT03871829
Terminated
The purpose of this study is to compare the efficacy (rate of very good partial response \[VGPR\] or better as best response as defined by the International Myeloma Working Group \[IMWG\] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab to evaluate daratumumab retreatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +107 locations
Conditions: Multiple Myeloma
Register for Updates
Adjuncts for Adductor Block: Dexamethasone,Dexmedetomidine, or Combination to Reduce Pain
NCT03643822
Recruiting
The aim of this multi-centered study is to evaluate the effects of two distinct Adductor Canal Block (ACB) adjuncts, dexamethasone and dexmedetomidine, and their combination, on postoperative analgesia in patients undergoing Anterior Cruciate Ligament (ACL) Repair.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/26/2025
Locations: Women's College Hospital, Toronto, Ontario
Conditions: ACL Injury
Register for Updates
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
NCT02649790
Completed
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California +45 locations
Conditions: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Register for Updates
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354
Recruiting
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +16 locations
Conditions: Multiple Myeloma
Register for Updates
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930
Active Not Recruiting
This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
03/13/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +242 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Register for Updates
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +50 locations
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Register for Updates
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
NCT03269136
Completed
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: UCSD Medical Center - Encinitas, Encinitas, California +36 locations
Conditions: Multiple Myeloma
Register for Updates
Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients
NCT05456542
Completed
The COSMIC trial will be a multicentred, national, parallel-group, pragmatic vanguard pilot trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas +4 locations
Conditions: Respiratory Failure
Register for Updates
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT03544281
Completed
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone \[Len/Dex (Treatment A)\] or Bortezomib Plus Dexamethasone \[Bor/Dex (Treatment B)\] in participants with RRMM, i.e., those who have relapsed or who are refractory to at least 1 line of approved therapy. Participants receiving treatment A, may continue combination treatment until the occurrence of progressive disea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: GSK Investigational Site, Birmingham, Alabama +25 locations
Conditions: Multiple Myeloma
Register for Updates
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358
Completed
This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, e... Read More
Gender:
ALL
Ages:
364 days and below
Trial Updated:
02/26/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +169 locations
Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Register for Updates
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
NCT05272826
Recruiting
This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/10/2025
Locations: London Health Sciences Centre, London, Ontario +1 locations
Conditions: Multiple Myeloma
Register for Updates
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00408005
Active Not Recruiting
This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is no... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
02/01/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +214 locations
Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Register for Updates